Author:
CHERNOVA N G,ZVONKOV E E,BADMAZHAPOVA D S,SINITSYNA M N,GREBENYUK L A,SIDOROVA Y V,KOSTINA I E,KOVRIGINA A M,OBUKHOVA T N,SUDARIKOV A B,SAVCHENKO V G
Abstract
Nodal anaplastic ALK-negative large cell lymphoma (nALCL, ALK-) is a Т-cell lymphoma that is characterized by aggressive clinical course and low sensitivity to СНОР (cyclophosphamide, doxorubicin, vincristine, prednisolone) and other chemotherapy regimen. In the article we present a literature review and describe our clinical case of nALCL, ALK-. For the first time a combination of Brentuximab vedotin with modified program NHL-BFM-90 was used as a first-line therapy. As a result of immunochemotherapy a complete antineoplastic effect was obtained. For consolidation of this effect high-dose chemotherapy with following autologous blood stem cell transplantation was performed. The chosen treatment tactics allowed to achieve a complete remission in a medium risk group patient.
Publisher
LLC Obyedinennaya Redaktsiya
Subject
General Medicine,Endocrinology, Diabetes and Metabolism,History,Family Practice
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献